Journal
NATURE MEDICINE
Volume 16, Issue 9, Pages 998-1000Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2199
Keywords
-
Funding
- US National Institutes of Health [P50NS38377, R01ES014470, R01-AG023593, R00-NS058111, NS36420]
- Army Medical Research and Materiel Command [DAMD17-02-1-0695]
- Mayo Foundation
- Michael J. Fox Foundation
Ask authors/readers for more resources
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
